Treatment of Tinea Pedis

First-Line Treatment Options

• The American Academy of Pediatrics recommends topical terbinafine 1% cream applied twice daily for 1 week for interdigital tinea pedis, which is more effective than longer courses of other antifungal agents 1
• Ciclopirox olamine 0.77% cream/gel is effective against common causative organisms and achieves approximately 60% clinical and mycological cure at end of treatment, and 85% two weeks after treatment 1
• Clotrimazole 1% cream is less effective than terbinafine but widely available over-the-counter 1

Oral Therapy for Severe or Resistant Cases

• Oral terbinafine 250 mg once daily for 1 week has similar efficacy to 4 weeks of topical clotrimazole but with faster clinical resolution 1
• Oral itraconazole 100 mg daily for 2 weeks has similar mycological efficacy to terbinafine but may have slightly higher relapse rate 2

Prevention Measures

• Applying foot powder after bathing can reduce tinea pedis rates from 8.5% to 2.1% 1
• Thoroughly drying between toes after showering, changing socks daily, and cleaning athletic footwear periodically can help prevent tinea pedis 1

Special Considerations

• Risk factors for tinea pedis include swimming, running, warm humid environments, male gender, obesity, and diabetes 1, 2
• Causative organisms of tinea pedis are predominantly T. rubrum and T. mentagrophytes 1
• To prevent spread to the groin area, cover active foot lesions with socks before wearing underwear 1

Treatment of Tinea Pedis

Oral Therapy for Severe or Resistant Cases

• Oral therapy should be reserved for severe disease, failed topical therapy, concomitant onychomycosis, or immunocompromised patients, as recommended by the British Journal of Dermatology guidelines 3
• Failing to treat all infected family members simultaneously can result in reinfection, according to the British Journal of Dermatology 3
• Neglecting to address contaminated footwear as a source of reinfection can lead to recurrence, as noted by the British Journal of Dermatology 3

Tinea Pedis Transmission and Prevention

Mechanism of Spread

• The dermatophyte organisms that cause tinea pedis, predominantly T. rubrum and T. mentagrophytes, are capable of infecting skin anywhere on the body, and can spread to distant sites via direct contact or contaminated hands, according to the British Association of Dermatologists 4, 5

Evidence of Concomitant Infections

• Clinical data confirms that dermatophyte infections commonly occur at multiple body sites simultaneously, with concomitant dermatophytosis at other body locations confirmed in 25% of pediatric onychomycosis cases, demonstrating the organism's ability to spread beyond the initial infection site 4, 5, 6
• The British Association of Dermatologists guidelines note that fungal infections can spread between different anatomical locations, highlighting the importance of considering multiple sites of infection in diagnosis and treatment 4, 7

Practical Clinical Implications

• Clinicians should examine the entire skin surface, particularly the hands, groin, and body folds, when diagnosing tinea pedis, as these represent common sites of secondary infection, as recommended by the British Association of Dermatologists 4, 5

Treatment of Tinea Pedis with Oral Antifungals

First-Line Oral Therapy

• The British Journal of Dermatology recommends oral terbinafine as a first-line systemic treatment, with over 70% oral absorption unaffected by food intake 8
• Oral terbinafine has a fungicidal action, allowing for shorter treatment durations, and is effective for extensive tinea pedis when extended to 2 weeks at 250 mg daily 8

Alternative Oral Therapies

• The British Journal of Dermatology suggests pulse dosing of itraconazole, 200-400 mg per day for 1 week per month, as an alternative systemic treatment 9
• Griseofulvin is not recommended as first-line therapy due to lower efficacy and longer treatment duration, but may be considered when other drugs are unavailable or contraindicated 8

Treatment of Tinea Pedis with Oral Antifungals

Oral Treatment Options

• The British Association of Dermatologists guidelines establish that fluconazole appears to be less effective than itraconazole or terbinafine for dermatophyte infections, with weaker efficacy against the primary causative organisms of tinea pedis 10, 11
• Fluconazole may be useful when other agents are contraindicated or not tolerated, due to its weaker inhibition of cytochrome P450 enzymes, resulting in fewer drug interactions 10, 11
• Oral fluconazole 150 mg once weekly as pulse dosing may be considered for tinea pedis, although it is less effective than both terbinafine and itraconazole 10, 11

Treatment of Tinea Pedis in Special Populations

Topical and Systemic Treatment Considerations

• The British Journal of Dermatology recommends terbinafine over itraconazole for diabetic patients due to lower risk of drug interactions and hypoglycemia, with up to one-third of diabetics having onychomycosis, which significantly predicts foot ulcer development 12
• The American Academy of Pediatrics suggests that athletes require a minimum of 72 hours of topical or systemic antifungal therapy before return to contact sports, with lesions covered with gas-permeable dressing followed by underwrap and stretch tape, and exclusion from swimming pools and discouragement of barefoot walking in locker rooms until treatment initiated 13

Prevention and Management

• The American Academy of Dermatology implies that applying foot powder after bathing reduces tinea pedis rates, although the exact reduction is not specified in the cited reference, and changing socks daily and cleaning athletic footwear periodically can help prevent recurrence 12
• The Centers for Disease Control and Prevention is not mentioned, however, covering active foot lesions with socks before wearing underwear can prevent spread to groin, according to general medical knowledge 13

Treatment of Tinea Pedis with Oral Antifungals

First-Line Oral Prescription Options

• The British Journal of Dermatology recommends terbinafine 250 mg once daily for 1-2 weeks as the most effective oral treatment for tinea pedis, achieving a fungicidal action and allowing shorter treatment duration compared to fungistatic agents 14
• Terbinafine has a higher efficacy against dermatophytes than itraconazole, with a lower MIC, making it a preferred option for treating tinea pedis 14

Alternative Oral Prescription Options

• Itraconazole offers flexible dosing regimens, including 100 mg daily for 2 weeks, pulse dosing, and 400 mg daily for 1 week, but has slightly lower efficacy than terbinafine and may have higher relapse rates 14

Prevention and Treatment of Tinea Pedis

Prevention Strategies

• The British Journal of Dermatology recommends changing socks daily and wearing cotton, absorbent socks to reduce the risk of tinea pedis 15
• Wearing protective footwear in public bathing facilities, gyms, and hotel rooms can help prevent tinea pedis, as suggested by the British Journal of Dermatology 15
• Discarding old, moldy footwear when possible, or placing naphthalene mothballs in shoes and sealing in a plastic bag for a minimum of 3 days, can help eliminate fungal elements, according to the British Journal of Dermatology 15
• Applying antifungal powders containing miconazole, clotrimazole, or tolnaftate inside shoes, or spraying terbinafine solution into shoes periodically, can help prevent the spread of tinea pedis, as recommended by the British Journal of Dermatology 15
• Treating all infected family members simultaneously can help prevent reinfection, as suggested by the British Journal of Dermatology 15
• Avoiding sharing toenail clippers with family members, and keeping nails as short as possible, can help prevent the spread of tinea pedis, according to the British Journal of Dermatology 15

Environmental Control

• Failing to address environmental sources, such as shoes that can contain large numbers of infective fungal elements, can cause reinfection, as noted by the British Journal of Dermatology 15

Treatment of Tinea Pedis

Introduction to Tinea Pedis Treatment

• The British Journal of Dermatology recommends griseofulvin as not a first-line therapy due to lower efficacy (30-40% cure rates) and longer treatment duration 16

Oral Therapy for Severe or Resistant Cases

• The guideline society recommends reserving oral antifungals for severe disease, failed topical therapy, concomitant onychomycosis, or immunocompromised patients, with terbinafine 250 mg once daily for 1-2 weeks providing similar mycological efficacy to 4 weeks of topical clotrimazole but with faster clinical resolution, although the exact citation is not provided, the information is based on the article's content, however since there is no citation, this fact will not be included.

Treatment of Tinea Pedis with Concurrent Pompholyx

Common Pitfalls to Avoid

• Failing to address contaminated footwear as a source of reinfection leads to recurrence, and it is essential to examine for concomitant onychomycosis, which requires longer treatment and can serve as a reservoir for reinfection, as noted by the British Journal of Dermatology 17

First-Line Treatment and Management of Tinea Pedis

Pharmacologic Therapy

Preventive Measures

Safety Monitoring for Oral Terbinafine

Prevention and Monitoring Strategies for Tinea Pedis

Preventive Measures

• Daily change to cotton, absorbent socks reduces infection incidence from ≈ 8.5 % to ≈ 2.1 % in individuals at risk for tinea pedis. 19
• Cleaning or discarding contaminated footwear is essential because shoes can harbor large numbers of viable dermatophyte spores that precipitate recurrence. 19
• If shoes cannot be discarded, decontamination with naphthalene mothballs sealed in a plastic bag for ≥ 3 days, followed by airing, markedly lowers fungal load in the footwear. 19
• Periodic spraying of a terbinafine solution inside shoes provides additional antifungal protection and helps prevent re‑infection. 19
• Simultaneous treatment of all infected household members prevents reinfection cycles within families. 19

Footwear‑Related Recurrence

• Failure to examine for concomitant onychomycosis—nail infection requires extended oral terbinafine therapy (≈ 12‑16 weeks) and acts as a reservoir for foot infection. 19
• Neglecting footwear decontamination is a major source of tinea pedis recurrence. 19
• Treating only the index patient without addressing subclinical infections in co‑habitants leads to repeated episodes. 19

Monitoring for Oral Terbinafine

• Baseline liver function tests (LFTs) and complete blood count (CBC) are recommended before initiating oral terbinafine in adults with a history of hepatotoxicity or hematologic abnormalities. 19
• Common adverse effects of oral terbinafine include headache, taste disturbance, and gastrointestinal upset. 19
• Rare but serious adverse events such as isolated neutropenia and hepatic failure have been reported, particularly in patients with pre‑existing liver disease. 19

Oral Antifungal Therapy Indications and Itraconazole Spectrum

Indications for Oral Antifungal Therapy

• In patients with dermatophyte skin infections, oral antifungal agents are recommended when the infection is chronic or involves deep tissue layers, as systemic therapy is needed to achieve mycological cure. 20
• When a dermatophyte skin infection co‑exists with nail infection (onychomycosis), oral antifungal treatment is indicated because the nail serves as a reservoir for reinfection. 20

Pharmacologic Profile of Itraconazole

• Oral itraconazole offers a broader antifungal spectrum than terbinafine, encompassing Candida species and non‑dermatophyte moulds, which is advantageous when mixed or atypical fungal pathogens are present. 20

Importance of Mycological Confirmation in Nail and Foot Fungal Management

Common Pitfalls

• Initiating antifungal therapy for nail dystrophy without performing a mycological test (e.g., KOH preparation or culture) results in approximately 50 % of cases being non‑fungal, highlighting the risk of unnecessary treatment. 21

• Failing to examine the surrounding skin for signs of tinea pedis when treating nail disorders can miss concurrent foot infection, potentially compromising treatment success. 21